A review of spinal cord stimulation systems for chronic pain

Paul Verrills 1
Chantelle Sinclair 2
Adele Barnard 2
1Metro Pain Group, 2Monash Clinical Research, Monash House, Clayton, Victoria, Australia

Abstract: Spinal cord stimulation (SCS) applications and technologies are fast advancing. New SCS technologies are being used increasingly in the clinical environment, but often there is a lag period between the clinical application and the publishing of high-quality evidence on safety and efficacy. Recent developments will undoubtedly expand the applicability of SCS, allowing more effective and individualized treatment for patients, and may have the potential to salvage patients who have previously failed neuromodulation. Already, high-level evidence exists for the safety, efficacy, and cost-effectiveness (Level I–II) of traditional SCS therapies in the treatment of chronic refractory low back with predominant limb pain (regardless of surgical history). More than half of all patients with chronic painful conditions experience sustained and significant levels of pain reduction following SCS treatment. Although only limited evidence exists for burst stimulation, there is now Level I evidence for both dorsal root ganglion SCS and high-frequency SCS that demonstrates compelling results compared with traditional therapies. The body of evidence built on traditional SCS research may be redundant, with newer iterations of SCS therapies such as dorsal root ganglion SCS, high-frequency SCS, and burst SCS. A number of variables have been identified that can affect SCS efficacy: implanter experience, appropriate patient selection, etiologies of patient pain, existence of comorbidities, including psychiatric illness, smoking status, and delay to SCS implant following pain onset. Overall, scientific literature demonstrates SCS to be a safe, effective, and drug-free treatment option for many chronic pain etiologies.

Keywords: spinal cord stimulator, neuromodulation, chronic pain, low back pain

Introduction to chronic pain

Chronic pain affects up to 20% of the population in developed nations. 1–4 This represents a profound impact on individuals and their families alongside the sizeable burden on employers, health care systems, and society in general. 1 When chronic pain occurs, it has the potential to become disease itself, and subsequently, chronic pain has emerged as a distinct phenomenon. 5

Management of chronic pain varies greatly between nations and even within nations. Literature supports a multidisciplinary approach as the standard of care, although various health care systems may not always support this concept consistently. 2

The current standard of care for chronic, noncancer pain typically includes many disciplines with the clinician developing an individualized treatment plan with the options of utilizing surgical interventions, pharmacology, and psychological and physical therapies. Opioid analgesics are often prescribed, despite the lack of clinical
evidence supporting their long-term use in the management of chronic pain. However, for many patients, this multidisciplinary approach is inadequate or ineffectual or is accompanied by the burden of side effects that are unacceptable and debilitating. Only at this late stage, referral for advanced neuromodulation techniques is considered and potentially trialed.

**Neuromodulation**

The field of neuromodulation for the treatment of pain has developed rapidly since the seminal paper on the electrical inhibition of pain by the stimulation of the dorsal column almost 50 years ago. The original term of dorsal column stimulation (SCS), SCS has been particularly effective as an adjunct in treating mixed neuropathic/nociceptive and neuropathic/radicular pain conditions such as failed back surgery syndrome (FBSS) and complex regional pain syndrome (CRPS). Neuromodulation therapies offer a treatment option that has minimal side effects and that is relatively safe and potentially reversible. SCS has been used to treat various pain conditions for many decades.

In traditional SCS therapies, the objective has been to replace the pain sensation with paresthesia that requires mapping of stimulation to the region of pain. The anticipation is that the electrical current alters pain processing by masking the sensation of pain with a comfortable tingling or paresthesia. Although patients mostly cope with paresthesia, a significant proportion report that the sensation is unpleasant, particularly with positional changes.

The stimulation is provided either through electrodes that are placed percutaneously into the epidural space or through a surgical paddle lead that is delivered via a laminotomy. These devices are capable of delivering pulse frequencies in the range of 2–1,200 Hz but are regularly utilized at 40–60 Hz.

Patients typically undergo a trial of neuromodulation with an externalized power source and if this trial proves to be positive and compelling, they subsequently have a subcutaneously implantable pulse generator for the long-term therapy.

In recent years, the next phase in the evolution of neuromodulation has become available with the development of dorsal root ganglion (DRG) SCS and the emerging use of two novel advances in stimulation frequencies, being high-frequency SCS (at 10,000 Hz) and burst SCS. These recent advances have improved the efficacy and expanded the applicability of SCS.

DRG SCS is a highly targeted form of neuromodulation therapy. Studies indicate that the DRG plays a key role in both nociceptive and neuropathic pain. DRG SCS is particularly useful in treating focal areas of pain, in particular those that have been difficult to target with traditional SCS systems such as groin and foot pain, by applying an innovative lead configuration and delivery system around the DRG.

High-frequency 10 SCS (HF10) presents a significant development in the evolution of SCS technologies. This involves application of a unique waveform at 10,000 Hz at a subthreshold level and therefore provides pain relief without any paresthesia. The majority of patients have a clear preference for paresthesia-free stimulation, and HF10 has been approved for clinical use in Australia and Europe since 2011 and has received Food and Drug Administration approval for the United States in 2015 for patients with chronic refractory pain of the trunk and/or limbs.

Burst SCS offers another novel mode of stimulation whereby conventional frequency parameters are provided in bursts of five pulses. The burst frequency is 40 Hz, and the pulse frequency is 500 Hz. Amplitude is reduced to try and achieve subthreshold stimulation, thereby providing pain relief with either reduced or no paresthesia.

**Efficacy**

The most recent systematic and comprehensive review of the effectiveness of SCS in treating chronic spinal pain demonstrated that there is a significant (Level I–II) evidence for SCS as a treatment for lumbar FBSS, where conventional medical management has failed. Furthermore, there is now Level I evidence for high-frequency stimulation but only limited evidence for burst stimulation.

In another recent and extensive review and meta-analysis of conventional SCS, more than half of all patients experienced significant pain relief. The authors observed that this was maintained for a mean follow-up period of 24 months. These reviews demonstrate that traditional SCS is an effective treatment option for a cohort that is notoriously difficult to treat.

The existing SCS literature has a large number of case series reports and only a limited number of high-quality, large prospective, consecutively recruited, randomized, or controlled comparative trials (Table 1). Furthermore, the literature, when viewed historically, must be tempered by the developments in skills, application, and technological advances. Hence, the traditional SCS papers have often reported successful pain relief as an undifferentiated generic pain that is not specific to the site of the primary or greatest pain (eg, back or leg). This observation is important because conventional SCS therapy has historically been prescribed...
Table 1 Selection of SCS literature with focus on back ± lower limb pain studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Design, cohort, sample size, follow-up</th>
<th>Reported findings</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barolat et al 28</td>
<td>2001</td>
<td>Prospective, multicenter observational case series n=41 Follow-up: 1 year Cohort: back and leg pain (with predominant pain in back)</td>
<td>Tests SCS systems with paddle electrodes and RF stimulator n=15 at 1 year At 12 months, 88% of patients reported fair-excellent pain relief for leg pain following SCS At 12 months, 68% of the patients reported fair-excellent pain relief for back pain following SCS</td>
<td>Groups pain relief of fair to excellent into one group Three patients dropped from study at 6 months: two due to inadequate pain relief and one classified as technical failure because power required to induce satisfactory paresthesia to control pain was inadequate. This methodology skews the outcome data</td>
</tr>
<tr>
<td>Kemler et al 56</td>
<td>2004</td>
<td>RCT n=54 (36 randomized to SCS + PT; 18 randomized to PT only) Follow-up: 2 years Cohort: CRPS</td>
<td>Tests either SCS + PT or PT only Significant improvement for those receiving SCS + PT: VAS mean improvement of 2.1 versus 0 cm for PT only Global perceived effect scale of 43% for SCS + PT group versus 6% for PT only</td>
<td>Excluded patients with primary or significant back pain Reoperation success rates tie with record low reported in literature Cross overs were counted as an outcome measure (ITT analysis questions this approach). Furthermore, despite some reoperation patients meeting successful outcome benchmark, they chose to cross over in an attempt to try and gain even further pain relief</td>
</tr>
<tr>
<td>North et al 57</td>
<td>2005</td>
<td>Prospective RCT (with optional cross over). n=50 Follow-up average of 3 years Cohort: FBSS</td>
<td>Tests either reoperation or SCS: 52% of patients receiving (through cross over or by randomization) SCS reported long-term success, compared with 19% receiving (through cross over or by randomization) reoperation. SCS is more successful than reoperation for treating radicular pain</td>
<td>45% experienced complications, 31% required surgical revision Authors comment that if data are managed in statistically conservative manner, then 33% of patients receiving SCS will have significantly less leg pain Comparative group receiving CMM but not placebo-controlled group</td>
</tr>
<tr>
<td>Kumar et al 58</td>
<td>2008</td>
<td>Prospective RCT n=100 (52 randomized to SCS, 48 randomized to CMM) Follow-up: 2 years Multicenter (across 12 centers internationally) Cohort: FBSS patients</td>
<td>Tests either SCS + CMM or CMM only: n=42 receiving stimulation at 2 years experienced significantly lower levels of leg pain but reported no difference in back pain SCS treatment led to better outcomes when measured using ODI, QOL, and patient satisfaction measures Analgesic intake and nondrug therapies did not change with either treatment</td>
<td>Study among very specific cohort/patient subpopulation Workcover patients could only receive SCS if they joined study SCS &gt; PC and UC Baseline pain Baseline Roland-Morris Disability Duration of pain Time in WC claim system</td>
</tr>
<tr>
<td>Turner et al 59</td>
<td>2010</td>
<td>Prospective, controlled cohort study SCS trial, n= 51; multidisciplinary PC n=39; UC, n=68 Follow-up at 6, 12, and 24 months Cohort: workers compensation recipients with FBSS</td>
<td>Tests SCS against UC and a multidisciplinary PC At 6 months, SCS patients had greater improvement in leg pain and function but with concomitant higher rates of opioid use At 12 and 24 months, the groups did not differ in rates of clinically meaningful leg pain of function or in work status Within 18 months, 19% had SCS removed</td>
<td>&lt;25% of SCS patients received psych assessment/screening SCS conversion rate was 58%, significantly lower than that reported in literature Implanter experience unclear No comparative or alternative population treated alongside WC group to act as control group</td>
</tr>
</tbody>
</table>

(Continued)
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Design, cohort, sample size, follow-up</th>
<th>Reported findings</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Vos et al62</td>
<td>2012</td>
<td>Prospective, observational case series n=41 Follow-up: 12 months Cohort: FBSS</td>
<td>Tests paddle-shaped SCS lead efficacy in capturing both back and leg pain Baseline leg pain mean of 8, dropped to 3.2, and baseline low back pain mean of 7.5, dropped to 4.2 at 12 months 71% experienced &gt;50% pain relief for legs and 51% of patients experienced &gt;50% pain relief for back</td>
<td>By 12 months, n=6 reported no or minimal pain relief, postulated that the FBSS and treatment thereof masked pain of different etiologies such as OA No control group</td>
</tr>
<tr>
<td>Moriyama et al63</td>
<td>2012</td>
<td>Prospective, observational, multicenter, open-label case series n=55 Follow-up: 6 months Cohort: CRPS, FBSS, and PVD</td>
<td>Tests that patients likely to benefit from SCS n=29 at 6-month follow-up where the overall VAS mean baseline of 74 mm dropped to 29.7 mm CRPS and PVD cases responding better than FBSS patients</td>
<td></td>
</tr>
<tr>
<td>Geurts et al26</td>
<td>2013</td>
<td>Prospective, observational, consecutive case series n=84 Follow-up at min 0.2 to max 11.9 years Cohort: CRPS-I</td>
<td>Tests long-term treatment efficacy of SCS for CRPS-I n=79 41% of patients experience ≥30% pain relief at endpoint Pain relief stabilizes and holds over time Having &lt;50% pain relief at SCS trial was a highly significant indicator of long-term treatment failure</td>
<td>Treatment success defined as ≥30% pain relief on baseline rather than ≥50% Minor common complications: lead migration in 23 patients, seven experience hardware malfunction requiring surgical intervention, seven infections, 44 battery replacements (mean battery life of 4.4 years). Data may reflect outmoded hardware/technologies used at start of trial No major complications</td>
</tr>
<tr>
<td>Van Buyten et al18</td>
<td>2013</td>
<td>Prospective, multicenter, open-label, observational study n=83 Follow-up: 6 months Cohort: majority FBSS (81%), predominantly low back pain</td>
<td>Tests safety and efficacy of HF SCS n=72 proceed to implant Back pain: mean VAS from 8.4 to 2.7 at 6 months Leg pain: mean VAS from 5.4 to 1.4 at 6 months 74% had ≥50% back pain relief at 6 months Subset of 14 had previously failed conventional SCS. HF10 able to capture or rescue eleven of these with good results</td>
<td>Note the use of both statistical mean and median. Mean baseline VAS scores reported but then median % change in pain was reported. No comparative group/control group – use of baseline for control</td>
</tr>
<tr>
<td>Al-Kaisy et al64</td>
<td>2014</td>
<td>Prospective, multicenter, observational case series n=72 Follow-up: 24 months Cohort: chronic unresponsive LBP (17% previously failed conventional SCS)</td>
<td>Tests safety and long-term efficacy of HF SCS on back and leg pain n=65 at 24-month follow-up Significant pain relief sustained Back pain: mean VAS from 8.4 to 3.3 at 2 years (P&lt;0.001) Leg pain: mean VAS from 5.4 to 2.3 (P&lt;0.001) HF SCS is safe treatment 60% had ≥50% back pain relief at 24 months</td>
<td>Observational study only</td>
</tr>
<tr>
<td>De Ridder et al65</td>
<td>2015</td>
<td>Retrospective, multicenter, comparative trial n=102 Follow-up: 2 weeks Cohort: majority FBSS and diabetic neuropathic pain. All patients had been using conventional SCS for at least 6 months</td>
<td>Tests efficacy of novel burst stimulation SCS against tonic/conventional SCS Overall burst stimulation had significantly better pain suppression over tonic stimulation: back pain was suppressed 29% better and limb pain 31% better when compared with tonic stimulation burst SCS able to “rescue” 62% of patients who no longer responded to tonic stimulation</td>
<td>No control group All participants were acclimated to conventional SCS prior to trial Very short 2-week study period</td>
</tr>
</tbody>
</table>
Tolerance to SCS has been observed in patients where HF10 therapy at 10,000 Hz; this therapy has evolved to better capture significant back, leg, and radicular pain. Indeed, predominant back pain has been an exclusionary factor in many studies. Recent studies that have included back pain as the primary source have involved HF10 therapy at 10,000 Hz; this therapy has evolved to better capture significant back, leg, and radicular pain. Tolerance to SCS has been observed in patients where pulse amplitude needs to be increased to achieve the same

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Design, cohort, sample size, follow-up</th>
<th>Reported findings</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kapural et al25</td>
<td>2015</td>
<td>Prospective, multicenter RCT n=198</td>
<td>Tests safety and efficacy of conventional versus HF SCS</td>
<td>Subjects and investigators could not be masked due to the nature of conventional SCS treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Follow-up: 12 months</td>
<td></td>
<td>Note the application of ≥40% rather than ≥50% reduction in back pain as eligibility measure for proceeding to implant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cohort: chronic back ± leg pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HF SCS therapy subjects did not experience paresthesia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The mean pre HF SCS VAS was 7.4, 12 months post HF SCS the mean VAS was 2.5</td>
<td>HF SCS recharged daily, whereas conventional typically had longer recharge intervals</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(67% decrease): conventional SCS 7.8 to 4.3 (44% decrease)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mean leg pain HF SCS pre 7.1 to 2.1 (70% decrease), conventional SCS 7.6 to 3.8</td>
<td>Patients naive to SCS of any form</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(49% decrease)</td>
<td></td>
</tr>
<tr>
<td>Russo et al29</td>
<td>2015</td>
<td>Retrospective, multicenter, observational case series n=256</td>
<td>Both the forms of SCS are safe and effective but HF is significantly more effective</td>
<td>Authors acknowledge that uncontrolled real-world application of SCS is different in controlled studies and therefore carries weaknesses such as no control group but alternatively offers insights into clinical experience</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Follow-up: 6 months</td>
<td>Tests efficacy of HF SCS in real world/routine clinical practice</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cohort: range of chronic pain diagnoses, including back only, back ± limb, head ± neck, complex pain patterns. 30% of cohort had previously failed conventional SCS</td>
<td>n=186 permanent implant</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Overall, –50% reduction in pain from baseline was sustained for 6 months. Back ± leg pain responded best</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Able to “rescue” majority of patients who had previously failed conventional SCS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tests DRG SCS as a treatment for neuropathic pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>n=32 permanent implant</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Overall pain reduced by 56% at 12 months and 60% of patients reported ≥50%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>improvement in pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pain localized to back was reduced by 42% (n=10), leg pain reduced by 62% (n=20), and foot pain reduced by 80% (n=10)</td>
<td></td>
</tr>
<tr>
<td>Liem et al15</td>
<td>2015</td>
<td>Prospective, multicenter, open-labeled observational study n=51</td>
<td>RELATIVE HIGH INCIDENCE OF ADVERSE EVENTS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Follow-up: 12 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cohort: several diagnoses, including FBSS, CRPS, radiculopathy, and lumbar stenosis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: Only studies with larger sample sizes and those published after 2000 were included. Adapted from Taylor RS, Desai MJ, Rigoard P, Taylor RJ. Predictors of pain relief following spinal cord stimulation in chronic back and leg pain and failed back surgery syndrome: a systematic review and meta-regression analysis. Pain Pract. 2014;14(6):489–505. With permission from John Wiley and Sons, copyright ©2013.25

Abbreviations: CMM, conventional medical management; CRPS, complex regional pain syndrome; DRG, dorsal root ganglion; FBSS, failed back surgery syndrome; HF, high frequency; ITT, intention-to-treat; min, minimum; max, maximum; OA, osteoarthritis; ODI, Oswestry disability index; PC, pain clinic; PT, physical therapy; PVD, peripheral vascular disease; QOL, quality of life; RCT, randomized controlled trial; RF, radio frequency; SCS, spinal cord stimulation; UC, usual care; VAS, visual analog scale; WC, workers compensation; LBP, low back pain.

for limb pain and has had only limited success in managing back pain. Indeed, predominant back pain has been an exclusionary factor in many studies. Recent studies that have included back pain as the primary source have involved
Tolerance cannot be predicted, and although the rate has not been widely reported in the literature, one study that researched over 10 years found it to be in the order of 29%. Possible causes for stimulation tolerance include neuroplasticity of pain transmission pathways, cellular or fibrotic changes in the tissues around the electrodes, patients reframing their pain over time, and psychological or psychiatric affective disorders. However, data pertaining to HF10 SCS have demonstrated no tolerance at this point.

Despite strict criteria for patient selection, a substantial number of patients fail to achieve optimal pain relief with SCS. A number of factors have been identified as possible indicators for treatment failure including tobacco and drug use, age, and lengthy delay between times of original pain onset to SCS implant.

Food and Drug Administration requirements for labeling the recent advanced iterations of SCS systems have led, for the first time, to Level I noninferiority comparative studies being undertaken to achieve labeling.

DRG SCS has been demonstrated as effective in multiple etiologies, including FBSS, CRPS, and chronic postsurgical pain. A recent study reported 1 year outcomes for DRG with overall pain scores reducing from 77.6 to 33.6 (P<0.005). Back pain reduced from 74.5 to 39.7 (P<0.05), and leg pain reduced from 74.6 to 28.7 (P<0.0005). The most compelling pain reduction happened for foot pain with scores reducing from 81.4 to 22.0 (P<0.05). Approximately 60% of the DRG SCS patients reported >50% improvement in their pain, and the pain localized to the back, legs, and feet was reduced by 42%, 62%, and 80%, respectively. Other outcome parameters including quality of life, mood, and satisfaction were improved and maintained throughout the 12 months.

The Accurate study is a US pivotal, noninferiority, randomized controlled trial (RCT) between DRG SCS and traditional SCS Medtronic system (Medtronic, Inc., Fridley, MN, USA). It is the largest RCT in the history of CRPS and causalgia, running from 2013 with primary completion estimated for 2018. The sample size for the study was 152; with 76 randomized to DRG SCS and 76 to the control arm using Medtronic traditional SCS. The inclusion criterion was leg pain for more than 6 months duration with a visual analog scale (VAS) score >6/10. In the subset analysis of the implant-only group, the data were even more impressive with 93% of the DRG SCS group meeting the primary endpoint at 3 months and 86% at 12 months. The traditional SCS arm had 72% meeting the primary endpoint and 70% at 12 months. The statistical analysis demonstrated noninferiority and, beyond that, superiority in the intention-to-treat, modified intention-to-treat, and implant-only groups. Furthermore, it was noted that 70% of patients achieved >80% pain reduction in the DRG group versus 52% in the Medtronic group. Target specificity for stimulation and pain relief was achieved in 94.5% of the DRG group and 61% of the Medtronic group.

The Sunburst study is set to run from 2013, with primary completion in 2016. It is a prospective randomized, non-inferiority controlled trial with the St Jude Medical Company (St Jude Medical, Inc. St Paul, MN, USA). Patients with intractable pain were randomized for the order they would receive either traditional or burst SCS. The study was performed with a one-to-one crossover at 12 weeks to the alternate therapy. The outcome measures included safety, effectiveness, and non-inferiority. The study was applied to an enriched cohort with patients who required to have pre-existing pain scores >6/10 and a >50% pain reduction in a traditional SCS trial using tonic stimulation. The sample size for the study was 121 with 100 people randomized. The sample size reported to date is 85 with a 24-week follow-up. The mean age of patients was 59 years, with a median duration of pain being 13 years.

The trial demonstrated noninferiority, and further statistical analysis demonstrated superiority for burst stimulation over tonic stimulation (P=0.035). The mean difference in burst pain reduction compared with tonic stimulation was 6 mm VAS points. This difference, while being statistically significant, does not meet the well-defined criteria for minimal clinical important difference.

Approximately 65% of the burst cohort experienced paresthesia-free stimulation and 69% of the cohort chose a preference for burst, with the majority of these having their preference related to no paresthesia, more so than better pain reduction.

The Senza RCT is a Level I study design run from 2012 with an estimated primary completion in 2015. This is the first-ever RCT of two SCS therapies with patients randomized to HF10 SCS (Senza System; Nevro Corp., Redwood City, CA, USA) or traditional SCS commercially available, Precision Plus, SCS system (Boston Scientific Corporation, Marlborough, MA, USA). It is a noninferiority study with the statistical capability of demonstrating superiority supervised by the Food and Drug Administration, and patients were monitored and programmed by the technicians associated with the respective devices. One hundred and ninety-eight
patients were randomized with 101 to the HF10 SCS group and 97 to traditional. Of these, 90 HF10 SCS patients and 81 traditional SCS patients were subsequently implanted.

The primary endpoint of >50% back pain reduction at 3 months was achieved in 80.9% of the HF10 SCS group versus 42.5% of the traditional SCS group. This met the criteria for noninferiority and statistical superiority (P < 0.001). Furthermore, at 12 months, this primary endpoint was met in 78.7% versus 51.3% of the patients.

Similarly, the primary endpoint for leg pain reduction was met in 80.0% of the HF10 SCS group versus 49.4% of the traditional SCS group. The responder rates for >50% leg pain reduction at 3 months was 83.1% in the HF10 SCS group and 55.0% in the traditional SCS group. The 12-month outcome data for the same groups were 78.7% versus 51.3% (superiority P value, P < 0.001).

Further subset analysis of patients who achieved VAS pain scores of ≤2.5 showed that for those with back pain, relief was maintained for 12 months 68.5% of the time for HF10 SCS, but only 35.8% of the time using traditional SCS. Whereas, for those with leg pain it was achieved 67.4% of the time for HF10 SCS versus 42.5% of the time with traditional SCS. Superiority P-values for HF10 were significant (P < 0.001).

These data demonstrate compelling evidence for treating complex back pain that was previously unheralded in the literature. Furthermore, paresthesia-free options allow the patient to keep stimulation on potentially 24 hours a day and hence sleep with the stimulator on and also perform activities such as driving.

**Economical or cost efficiency**

Health care policy and funding decisions require evidence of clinical efficacy and information around cost-effectiveness of treatments. Consequently, there have been a number of studies considering the economic factors associated with SCS. Most recently, a 2015 study investigating the cost-effectiveness of conventional medical management with or without SCS in patients with FBSS compared a summary of the total direct and indirect costs incurred in the 12 months prior and 24 months following SCS. The costs were scaled to values of €2,009. The total pre-SCS treatment costs were equivalent to €6,567/patient-year. The year of implant incurred a significant increase in costs of €20,902/patient-year, mainly attributed to the high cost of the SCS devices. In the following 12–14 months, SCS implant had dropped to €5,430/patient-year. Applying the current United Kingdom National Health Service threshold (intervention considered not cost-effective if the incremental cost-effectiveness ratio is higher than €45,000/quality-adjusted life year [QALY]), SCS with conventional medical management would be considered cost-effective around 40% of the time. However, if the willingness-to-pay threshold was shifted to €60,000/QALY, SCS would be considered cost-effective by the National Health Service with an average of 80% of the time.

In 2013, a study developed models to evaluate the cost-effectiveness of SCS and conventional medical management together compared with conventional medical management alone for patients with FBSS and CRPS. Health effects were expressed as QALYs and costs were expressed as Canadian dollars (CANS) scaled to 2012. The models were extrapolated over a 20 year-time period with 3.5% discounts annually (as per National Institute of Clinical Excellence suggestion). The modeling data showed that SCS with conventional medical management is cost-effective compared with conventional medical management alone for all presentations, with a cost-effectiveness ratio for SCS of CANS9293 for FBSS and CANS11,216 for CRPS per QALY gained.

In a study in 2010, the cost-effectiveness of SCS with conventional medical management was compared with conventional medical management alone in CRPS patients. This study models economic costs using a simulated model population, employing parameters and assumptions set from previously published randomized trials. Here, SCS was shown to be cost-effective in select CRPS patients, with a probability exceeding 80% that SCS is cost-effective where the willingness to pay is set for a maximum of £30,000 per QALY.
the willingness to pay is set for a maximum of £20,000 per QALY.42

In 2008, a systematic review for cost-effectiveness of three studies where FBSS patients had been treated with SCS demonstrated that SCS is both more effective and less costly than conventional medical management alone in the long-term but there are high upfront implant costs associated with SCS implantation and maintenance.43

In 2008, another study reported the generic health-related quality of life and costs of SCS at 6 months follow-up (using data from the PROCESS trial) compared to the quality of life, resource consumption, and costs of conventional medical management alone in patients with FBSS.39 The study found that the mean total health care costs for the SCS group were significantly higher (€12,653) than the conventional medical management group (€2,594), when scaled for UK 2005–2006 national data.39

This result reflects the high upfront costs of SCS over the limited 6-month follow-up period. The authors showed that 15% of the additional mean cost of SCS was offset within 6 months by a reduced use of drug and nondrug therapies. They also demonstrated a gain in quality of life over the same period which was significantly greater for the SCS group. The study concludes that, over the short term, SCS treatment results in greater healthcare costs but also generates important health improvements for the patients over the same period.39

Cost-efficacy studies show that despite significant initial costs, SCS compared with other conventional treatments available to chronic pain patients results in long-term reductions in health care costs, which offset the high initial treatment costs over time.44

Safety and tolerability

In the literature, SCS is reported as a safe procedure due to its reversible and minimally invasive characteristics.39 Although catastrophic complications are possible, they are very rare. However, the incidence of minor complications of SCS has been reported at around 30%–40%.31,30,31,45–47 These minor complications tend to occur within 12 months of implantation and are readily reversible and generally resolved.13

The complications are divided into three main categories: mechanical, biological, and technique-related.32 Complications of a mechanical origin are more common than those of biological origin.31,45 Historically, hardware-related complications occurred at a rate of between 24%–50%, whereas adverse biological events occurred in 7.5% of cases.30

Mechanical complications include lead fracture or disconnection, which has a reported incidence of between 5% and 9%; lead migration has a reported incidence between 0% and 27%; implantable pulse generator failure occurred at a reported frequency of 1.7%11,30 These complications can be minimized by using appropriate leads, anchoring, and suturing techniques. Furthermore, minimizing patient movements in the first 3 months after surgery allows for postoperative scarring of leads into place.30

Kapural et al demonstrated that lead migration of significance and requiring intervention in both the HF10 and traditional SCS arms occurred <5%. This most likely reflects improvements in both lead design and the anchoring systems used (Figures 1–3).14,22,26,48

Biological complications include infection, allergic reaction, pain at implant site, implantable pulse generator seroma, epidural fibrosis, epidural hematoma, dural

Figure 1 (A) Posterior anterior fluoroscopy image and (B) lateral fluoroscopy image of T8-T10 placement of linear leads (Nevro Corp.) for the treatment of chronic back and leg pain.

Note: Images courtesy of Metro Pain Group.

Abbreviations: L, left; R, right.
puncture, and, rarely, neurological injury. The most common biological complication is infection with a rate between 3% and 8%, and the majority of these are superficial. As is seen in the more recent literature, incidence of infection can be minimized via pre and postoperative antibiotic use and appropriate skin preparation. The occurrence of dural puncture is reported as between 0.3% and 2%. Other adverse biological events such as epidural fibrosis, compressive phenomenon, or spinal cord injury, while serious, are rare.

The Neuromodulation Appropriateness Consensus Committee has recommended a number of criteria and adaptations to practice to help reduce complications: physician training and mentoring, the appropriate and careful selection of patients, a continued focus on equipment development and innovation, as well as the dissemination and application of practice and research-based advances.

Patient-focused perspectives

As this field strives to provide high-quality, transparent, and independent empirical evidence for SCS therapies, it is possible to overlook the primary rationale for SCS treatment in the first place: patient benefit. Patients suffering from chronic pain are often misdiagnosed or treated inappropriately. Improvements to training in pain management are needed, beginning at the undergraduate medical level. At present, the time allocated to pain management is generally inadequate; for instance, in the United Kingdom, the median time spent on pain management by a medical student is 13 hours, and sometimes it is as little as 6 hours. Indeed, when “the undergraduate training of all healthcare professionals is analyzed, education about the identification, assessment, and treatment of pain represents less than 1% of university-based teaching – yet pain is the most common reason for patients to consult their general practitioner.”

The ensuing repercussions may include inadequate diagnosis, inappropriate treatments, and extended periods of mismanagement. Further complicating the treatment of this cohort has been the inclusion of neuromodulation therapies as a treatment of last resort. Yet research has shown that shifting SCS forward in the treatment algorithm of refractory chronic pain is associated with better patient outcomes. In recent years, many researchers and practitioners have included patient satisfaction (alongside empirical measures) as a clinically useful metric for assessing SCS treatment success. When reported, overall patient satisfaction is high for the vast majority of SCS patients, perhaps reflecting the efficacy of SCS treatment, but may also reflect factors such
as limitations of alternative treatments, safety, and tolerability of SCS and the rapidity of onset and durability of SCS treatment.56

Moreover, under current arrangements, most patients access SCS treatment through private health insurance schemes or through compensatory bodies such as workers compensation schemes.57 For patients who do not qualify for these funding systems, the immediate cost outlay would likely post a significant financial barrier to treatment.57 The SCS specialty should aim to support the provision of equitable and accessible treatment for all.

**Conclusion**

Significant evidence exists for traditional SCS as a safe, clinical, and cost-effective treatment for many chronic pain conditions. Indeed, the field is rapidly evolving, and there is now Level I evidence for newer techniques including HF10 SCS and DRG SCS, which demonstrate dramatic improvements in overall efficacy in reducing pain in specific conditions, including failed back surgery, back pain, neuropathic leg pain, CRPS, and causalgia.

Furthermore, the field has increasingly met the challenge of not only having newer devices to achieve these outcomes but concurrently reducing the risks of complications and adverse events.

The data supporting SCS in its multiple forms are compelling and have reached a level that now demands that this therapy be considered earlier in the treatment continuum and to be no longer regarded as simply an end-stage salvage therapy.

**Acknowledgment**

The authors wish to thank anonymous reviewers for constructive comments that have led to an improved paper.

**Disclosure**

Paul Verrills is a consultant to NEVRO Corp and St Jude Medical Advisory and peer to peer teaching. The other authors (AB and CS) declare no conflicts of interest.

**References**


